D
Donald A. Mahler
Researcher at Dartmouth College
Publications - 124
Citations - 9289
Donald A. Mahler is an academic researcher from Dartmouth College. The author has contributed to research in topics: COPD & Indacaterol. The author has an hindex of 44, co-authored 114 publications receiving 8526 citations. Previous affiliations of Donald A. Mahler include Yale University & Valley Regional Hospital.
Papers
More filters
Journal ArticleDOI
Evaluation of Clinical Methods for Rating Dyspnea
TL;DR: The results show that the BDI, MRC scale, and OCD provide significantly related measures of Dyspnea, and the clinical ratings of dyspnea correlate significantly with physiologic parameters of lung function; and breathlessness may be related to the pathophysiology of the specific respiratory disease.
Journal ArticleDOI
Outcomes for COPD pharmacological trials: From lung function to biomarkers
Mario Cazzola,William MacNee,Fernando J. Martinez,Klaus F. Rabe,L. G. Franciosi,Peter J. Barnes,Vito Brusasco,PS Burge,Peter M.A. Calverley,Bartolome R. Celli,Paul W. Jones,Donald A. Mahler,Barry Make,Marc Miravitlles,Clive P. Page,Paolo Palange,David G. Parr,Massimo Pistolesi,S. I. Rennard,MP Rutten-van Mölken,Robert A. Stockley,Sean D. Sullivan,Jadwiga A. Wedzicha,Emiel F.M. Wouters +23 more
TL;DR: The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers.
Journal ArticleDOI
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Donald A. Mahler,James F. Donohue,Robert A. Barbee,M. Goldman,Nicholas J. Gross,Michael E. Wisniewski,Steven W. Yancey,Bradford A. Zakes,Kathleen Rickard,Wayne Anderson +9 more
TL;DR: These collective data support the use of salmeterol as first-line bronchodilator therapy for the long-term treatment of airflow obstruction in patients with COPD.
Journal ArticleDOI
The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease
Stephen I. Rennard,Charles Fogarty,Steven G. Kelsen,William Long,Joe W. Ramsdell,James Allison,Donald A. Mahler,Constantine Saadeh,Thomas Siler,Phillip Snell,Phillip Korenblat,William L. Smith,Mitchell Kaye,Michael Mandel,Charles E. Andrews,Rachakonda Prabhu,James F. Donohue,Rosemary Watt,Kim Hung Lo,Rozsa Schlenker-Herceg,Elliot S. Barnathan,John J. Murray +21 more
TL;DR: Subjects with moderate to severe COPD did not benefit from treatment with infliximab and the impact of inflIXimab on malignancy risk in patients with COPD needs to be further elucidated.
Journal ArticleDOI
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
James F. Donohue,Charles Fogarty,Jan Lötvall,Donald A. Mahler,Heinrich Worth,Arzu Yorgancioglu,Amir Iqbal,James Swales,Roger Owen,Mark Higgins,Benjamin Kramer +10 more
TL;DR: Indacaterol was an effective once-daily bronchodilator and was at least as effective as tiotropium in improving clinical outcomes for patients with COPD.